PAR2 Agonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Institut National de la Recherche Agronomique (INRA)
InventorsNathalie Vergnolle, Béatrice Riteau
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing influenza virus type A infections. More particularly, the invention relates to a PAR2 agonist for use in the treatment or prevention of an influenza virus type A infection.
Claims5
1-3. (canceled)
A method for treating or preventing an influenza virus type A infection in a subject in need thereof, comprising the step of
- administering to said subject a PAR2 agonist.
A PAR2 activating peptide selected from the group consisting of SLIGRL (SEQ ID NO:
- 1) or SLIGKV (SEQ ID NO:
- 2).
Dependencies are inferred from the claim text.